Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.

Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM.

Curr Opin Urol. 2020 Jan;30(1):98-105. doi: 10.1097/MOU.0000000000000685.

PMID:
31644433
2.

Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.

Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.

J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]

PMID:
31601699
3.

The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier.

Kruijff RM, Raavé R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchertseifer F, Heskamp S, Denkova AG.

Sci Rep. 2019 Aug 12;9(1):11671. doi: 10.1038/s41598-019-48298-8.

4.

Development of Targeted Alpha Therapy from Bench to Bedside.

Morgenstern A, Bruchertseifer F.

J Med Imaging Radiat Sci. 2019 Aug 9. pii: S1939-8654(19)30341-8. doi: 10.1016/j.jmir.2019.06.046. [Epub ahead of print]

PMID:
31405818
5.

Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.

Bruchertseifer F, Kellerbauer A, Malmbeck R, Morgenstern A.

J Labelled Comp Radiopharm. 2019 Sep;62(11):794-802. doi: 10.1002/jlcr.3792. Epub 2019 Aug 1.

PMID:
31369165
6.

Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):1988. doi: 10.1007/s00259-019-04401-9.

7.

Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG.

Feuerecker B, Michalik M, Hundshammer C, Schwaiger M, Bruchertseifer F, Morgenstern A, Seidl C.

Sci Rep. 2019 Jun 5;9(1):8294. doi: 10.1038/s41598-019-44484-w.

8.

Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617.

Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T, Boshomane TG, Mokoala KK, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1756-1757. doi: 10.1007/s00259-019-04354-z. Epub 2019 May 21. No abstract available.

PMID:
31115638
9.

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay.

Schmeiser HH, Muehlbauer KR, Mier W, Baranski AC, Neels O, Dimitrakopoulou-Strauss A, Schmezer P, Kratochwil C, Bruchertseifer F, Morgenstern A, Kopka K.

Mutagenesis. 2019 Sep 20;34(3):239-244. doi: 10.1093/mutage/gez007.

10.

PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY.

Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel F, Van de Wiele C, Morgenstern A.

J Nucl Med. 2019 May 17. pii: jnumed.119.229229. doi: 10.2967/jnumed.119.229229. [Epub ahead of print]

PMID:
31101746
11.

Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy.

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget JP.

Clin Cancer Res. 2019 Aug 1;25(15):4775-4790. doi: 10.1158/1078-0432.CCR-18-3295. Epub 2019 May 6.

PMID:
31061069
12.

Measurement of absolute γ-ray emission probabilities in the decay of 227Ac in equilibrium with its progeny.

Marouli M, Lutter G, Pommé S, Van Ammel R, Hult M, Pierre S, Dryák P, Carconi P, Fazio A, Bruchertseifer F, Morgenstern A.

Appl Radiat Isot. 2019 Feb;144:34-46. doi: 10.1016/j.apradiso.2018.08.023. Epub 2018 Aug 30.

13.

Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma.

Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622. doi: 10.1007/s00259-018-4225-7. Epub 2018 Nov 29.

PMID:
30498897
14.

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. doi: 10.1007/s00259-018-4167-0. Epub 2018 Sep 19. Erratum in: Eur J Nucl Med Mol Imaging. 2019 Jun 26;:.

15.

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.

Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, Morgenstern A, Hein M, Plinkert P, Haberkorn U, Bulut OC.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147. doi: 10.1007/s00259-018-4135-8. Epub 2018 Aug 27.

PMID:
30151743
16.

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics.

Šimeček J, Hermann P, Seidl C, Bruchertseifer F, Morgenstern A, Wester HJ, Notni J.

EJNMMI Res. 2018 Aug 8;8(1):78. doi: 10.1186/s13550-018-0431-3.

17.

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F.

Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524. Review.

18.

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644. doi: 10.1007/s00259-018-4015-2. Epub 2018 Apr 30.

19.

Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.

Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M, Kashani R, Koch J, Sosabowski J, Foster J, Chouin N, Bruchertseifer F, Morgenstern A, Kotzki PO, Navarro-Teulon I, Pouget JP.

J Nucl Med. 2018 Aug;59(8):1234-1242. doi: 10.2967/jnumed.118.208611. Epub 2018 Apr 19.

20.

Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.

Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B, D'Alessandria C, Pfob C, Nekolla S, Apostolidis C, Mirzadeh S, Gschwend JE, Schwaiger M, Scheidhauer K, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371. doi: 10.1007/s00259-018-4003-6. Epub 2018 Apr 11.

PMID:
29644393
21.

Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy.

Nosanchuk JD, Jeyakumar A, Ray A, Revskaya E, Jiang Z, Bryan RA, Allen KJH, Jiao R, Malo ME, Gómez BL, Morgenstern A, Bruchertseifer F, Rickles D, Thornton GB, Bowen A, Casadevall A, Dadachova E.

Sci Rep. 2018 Apr 3;8(1):5466. doi: 10.1038/s41598-018-23889-z.

22.

In vitro evaluation of 225 Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme.

Majkowska-Pilip A, Rius M, Bruchertseifer F, Apostolidis C, Weis M, Bonelli M, Laurenza M, Królicki L, Morgenstern A.

Chem Biol Drug Des. 2018 Jul;92(1):1344-1356. doi: 10.1111/cbdd.13199. Epub 2018 Apr 23.

PMID:
29611298
23.

Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy.

Cędrowska E, Pruszynski M, Majkowska-Pilip A, Męczyńska-Wielgosz S, Bruchertseifer F, Morgenstern A, Bilewicz A.

J Nanopart Res. 2018;20(3):83. doi: 10.1007/s11051-018-4181-y. Epub 2018 Mar 20.

24.

Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer.

Pruszynski M, D'Huyvetter M, Bruchertseifer F, Morgenstern A, Lahoutte T.

Mol Pharm. 2018 Apr 2;15(4):1457-1466. doi: 10.1021/acs.molpharmaceut.7b00985. Epub 2018 Mar 7.

PMID:
29502411
25.

The therapeutic potential of polymersomes loaded with 225Ac evaluated in 2D and 3D in vitro glioma models.

de Kruijff RM, van der Meer AJGM, Windmeijer CAA, Kouwenberg JJM, Morgenstern A, Bruchertseifer F, Sminia P, Denkova AG.

Eur J Pharm Biopharm. 2018 Jun;127:85-91. doi: 10.1016/j.ejpb.2018.02.008. Epub 2018 Feb 8.

26.

Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.

Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Teoh EJ, Bottomley D, Scarsbrook A, Payne H, Afaq A, Bomanji J, van As N, Chua S, Hoskin P, Chambers A, Cook GJ, Warbey VS, Chau A, Ward P, Miller MP, Stevens DJ, Wilson L, Gleeson FV, Scheidhauer K, Seidl C, Autenrieth M, Bruchertseifer F, Apostolidis C, Kurtz F, Horn T, Pfob C, Schwaiger M, Gschwend J, D'Alessandria C, Morgenstern A, Uprimny C, Kroiss A, Decristoforo C, von Guggenberg E, Nilica B, Horninger W, Virgolini I, Rasul S, Poetsch N, Woehrer A, Preusser M, Mitterhauser M, Wadsak W, Widhalm G, Mischkulnig M, Hacker M, Traub-Weidinger T, Wright CL, Binzel K, Wuthrick EJ, Miller ED, Maniawski P, Zhang J, Knopp MV, Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L, Mairinger S, Filip T, Sauberer M, Flunkert S, Wanek T, Stanek J, Okamura N, Langer O, Kuntner C, Fornito MC, Balzano R, Di Martino V, Cacciaguerra S, Russo G, Seifert D, Kleinova M, Cepa A, Ralis J, Hanc P, Lebeda O, Mosa M, Vandenberghe S, Mikhaylova E, Borys D, Viswanath V, Stockhoff M, Efthimiou N, Caribe P, Van Holen R, Karp JS, Binzel K, Zhang J, Wright CL, Maniawski P, Knopp MV, Haller PM, Farhan C, Piackova E, Jäger B, Knoll P, Kiss A, Podesser BK, Wojta J, Huber K, Mirzaei S, Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Sibilia M, Langer O, Fornito MC, Russello M, Russo G, Balzano R, Sorko S, Gallowitsch HJ, Kohlfuerst S, Matschnig S, Rieser M, Sorschag M, Lind P, Ležaič L, Rep S, Žibert J, Frelih N, Šuštar S, Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, Kulkarni HR, Fornito MC, Cacciaguerra S, Balzano R, Di Martino GV, Russo G, Thomson WH, Kudlacek M, Karik M, Farhan C, Rieger H, Pokieser W, Glaser K, Mirzaei S, Petz V, Tugendsam C, Buchinger W, Schmoll-Hauer B, Schenk IP, Rudolph K, Krebs M, Zettinig G, Zoufal V, Wanek T, Krohn M, Mairinger S, Stanek J, Sauberer M, Filip T, Pahnke J, Langer O, Weitzer F, Pernthaler B, Salamon S, Aigner R, Koranda P, Henzlová L, Kamínek M, Váchalová M, Bachleda P, Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom JN, Orlova A, Tolmachev V, Decristoforo C, Kaeopookum P, Summer D, Orasch T, Lechner B, Petrik M, Novy Z, Rangger C, Haas H, Decristoforo C.

EJNMMI Res. 2018 Jan 23;8(Suppl 1):5. doi: 10.1186/s13550-017-0354-4. No abstract available.

27.

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.

J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.

28.

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.

Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, Haberkorn U, Giesel FL.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37. doi: 10.1007/s00259-017-3817-y. Epub 2017 Sep 11.

29.

Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.

Wurzer A, Seidl C, Morgenstern A, Bruchertseifer F, Schwaiger M, Wester HJ, Notni J.

Chemistry. 2018 Jan 12;24(3):547-550. doi: 10.1002/chem.201702335. Epub 2017 Sep 14.

30.

Improved 225Ac daughter retention in InPO4 containing polymersomes.

de Kruijff RM, Drost K, Thijssen L, Morgenstern A, Bruchertseifer F, Lathouwers D, Wolterbeek HT, Denkova AG.

Appl Radiat Isot. 2017 Oct;128:183-189. doi: 10.1016/j.apradiso.2017.07.030. Epub 2017 Jul 16.

PMID:
28734193
31.

In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.

Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W, Konijnenberg M.

PLoS One. 2017 Jul 21;12(7):e0181473. doi: 10.1371/journal.pone.0181473. eCollection 2017.

32.

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.

Nedrow JR, Josefsson A, Park S, Bäck T, Hobbs RF, Brayton C, Bruchertseifer F, Morgenstern A, Sgouros G.

EJNMMI Res. 2017 Dec;7(1):57. doi: 10.1186/s13550-017-0303-2. Epub 2017 Jul 18.

33.

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.

Gustafsson-Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S.

EJNMMI Res. 2017 Dec;7(1):38. doi: 10.1186/s13550-017-0283-2. Epub 2017 Apr 24.

34.

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A.

J Nucl Med. 2017 Oct;58(10):1624-1631. doi: 10.2967/jnumed.117.191395. Epub 2017 Apr 13.

35.

Alpha-particle radiotherapy: For large solid tumors diffusion trumps targeting.

Zhu C, Sempkowski M, Holleran T, Linz T, Bertalan T, Josefsson A, Bruchertseifer F, Morgenstern A, Sofou S.

Biomaterials. 2017 Jun;130:67-75. doi: 10.1016/j.biomaterials.2017.03.035. Epub 2017 Mar 25.

PMID:
28365545
36.

213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S.

Cancer Biother Radiopharm. 2017 Mar;32(2):67-73. doi: 10.1089/cbr.2016.2155.

PMID:
28301262
37.

A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer.

Revskaya E, Jiang Z, Morgenstern A, Bruchertseifer F, Sesay M, Walker S, Fuller S, Lebowitz MS, Gravekamp C, Ghanbari HA, Dadachova E.

Cancer Biother Radiopharm. 2017 Mar;32(2):57-65. doi: 10.1089/cbr.2016.2141.

38.

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.

Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.

J Nucl Med. 2017 Jun;58(6):926-933. doi: 10.2967/jnumed.116.187021. Epub 2017 Feb 23.

39.

Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy.

Piotrowska A, Męczyńska-Wielgosz S, Majkowska-Pilip A, Koźmiński P, Wójciuk G, Cędrowska E, Bruchertseifer F, Morgenstern A, Kruszewski M, Bilewicz A.

Nucl Med Biol. 2017 Apr;47:10-18. doi: 10.1016/j.nucmedbio.2016.11.005. Epub 2016 Nov 17.

PMID:
28043005
40.

Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents.

Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC.

Theranostics. 2017 Jan 1;7(1):1-8. doi: 10.7150/thno.15124. eCollection 2017.

41.

Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy.

Chan HS, de Blois E, Konijnenberg MW, Morgenstern A, Bruchertseifer F, Norenberg JP, Verzijlbergen FJ, de Jong M, Breeman WAP.

EJNMMI Radiopharm Chem. 2017;1(1):9. doi: 10.1186/s41181-016-0014-4. Epub 2016 May 14. Erratum in: EJNMMI Radiopharm Chem. 2018 Nov 26;3:13.

42.

[Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].

Autenrieth ME, Horn T, Kurtz F, Nguyen K, Morgenstern A, Bruchertseifer F, Schwaiger M, Blechert M, Seidl C, Senekowitsch-Schmidtke R, Gschwend JE, Scheidhauer K.

Urologe A. 2017 Jan;56(1):40-43. doi: 10.1007/s00120-016-0273-4. German.

PMID:
27885456
43.

Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.

Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, Casadevall A, Dadachova E.

Front Med (Lausanne). 2016 Sep 26;3:41. eCollection 2016.

44.

Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.

Sempkowski M, Zhu C, Menzenski MZ, Kevrekidis IG, Bruchertseifer F, Morgenstern A, Sofou S.

Langmuir. 2016 Aug 23;32(33):8329-38. doi: 10.1021/acs.langmuir.6b01464. Epub 2016 Aug 8.

PMID:
27468779
45.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A.

J Nucl Med. 2016 Dec;57(12):1941-1944. Epub 2016 Jul 7.

46.

[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].

Ménager J, Gorin JB, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, Davodeau F, Kraeber-Bodéré F, Chérel M, Gaschet J, Guilloux Y.

Med Sci (Paris). 2016 Apr;32(4):362-9. doi: 10.1051/medsci/20163204014. Epub 2016 May 2. Review. French.

47.

Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.

Yoshida T, Jin K, Song H, Park S, Huso DL, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F, Morgenstern A, Sgouros G, Sukumar S.

Oncotarget. 2016 May 31;7(22):33306-15. doi: 10.18632/oncotarget.8949.

48.

Long-Term Toxicity of 213Bi-Labelled BSA in Mice.

Dorso L, Bigot-Corbel E, Abadie J, Diab M, Gouard S, Bruchertseifer F, Morgenstern A, Maurel C, Chérel M, Davodeau F.

PLoS One. 2016 Mar 16;11(3):e0151330. doi: 10.1371/journal.pone.0151330. eCollection 2016.

49.

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.

Chan HS, Konijnenberg MW, de Blois E, Koelewijn S, Baum RP, Morgenstern A, Bruchertseifer F, Breeman WA, de Jong M.

EJNMMI Res. 2016 Dec;6(1):6. doi: 10.1186/s13550-016-0162-2. Epub 2016 Jan 20.

50.

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.

Derrien A, Gouard S, Maurel C, Gaugler MH, Bruchertseifer F, Morgenstern A, Faivre-Chauvet A, Classe JM, Chérel M.

Front Med (Lausanne). 2015 Dec 21;2:88. doi: 10.3389/fmed.2015.00088. eCollection 2015.

Supplemental Content

Loading ...
Support Center